CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
PTC Therapeutics (PTCT) PT Lowered to $45 at Truist Securities; 'PTC isn't dead'
September 18, 2023 6:14 AM EDTTruist Securities analyst Robyn Karnauskas lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $45.00 (from $60.00) while maintaining a Buy rating.
THE analyst commented, "In addition to the negative CHMP decision, we believe concerns about cash position and mgmt's ability to... More
PTC Therapeutics (PTCT) PT Lowered to $53 at JPMorgan, 'Late Stage Assets Remain Significantly Underappreciated'
September 15, 2023 12:50 PM EDTJPMorgan analyst Eric Joseph lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $53.00 (from $70.00) while maintaining a Overweight rating.
The analyst comments "Were lowering our Dec -24 PT ($53/sh vs $70 prior) but maintaining our Overweight rating following the negative CHMP opinion regarding full / extended conditional marketing authorization... More
